slides · global inventory
Table
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 60,568
Current window 43,951-43,980
Pages 2,019
Rows per page 30
Component
43,951-43,980 of 60,568
13
The table includes a footnote explaining the organic net sales growth calculation.GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations 1 hit
14
The table includes a breakdown of adjustments (A-H) with corresponding footnotes on the right.GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations 1 hit
15
Includes detailed line-item adjustments (A-J) with corresponding commentary.GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations 1 hit
16
Includes footnotes A and B explaining specific adjustments.GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations 1 hit
17
Includes a commentary section explaining the nature of the adjustments (A-E).GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations 1 hit
18
Includes footnotes regarding unamortized discounts and deferred financing costs.GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations 1 hit
19
GMS | Results Presentation Deck | 19 slidesGMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations 1 hit
11
The slide uses a combination of bar charts for preclinical cytokine release and a table for clinical outcomes to demonstrate the superiority of the NXC-201 CD8 hinge optimization.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Problem & Complication1 hit
14
The slide explicitly notes that these are not head-to-head results and caution should be exercised in comparison.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Problem & Complication1 hit
22
The slide uses a table structure to contrast patient segments and includes a bar chart visualization for patient growth.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
24
Includes a footnote citing FDA approval precedents for similar single-arm studies.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
28
The slide uses a standard pharmaceutical pipeline table format.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
29
Includes a comparative table of clinical outcomes (ORR/CR) for NXC-201 vs. Allogeneic CAR-T and Bispecifics.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
31
The slide uses a red dashed box to highlight the primary efficacy metrics for comparison.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · David Goliath1 hit
32
The table uses a cross-trial comparison format. The red dashed box highlights the key clinical data rows.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · David Goliath1 hit
41
The table displays clinical trial data for NXC-201, specifically focusing on safety profiles and management of side effects.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
42
The slide highlights specific safety data points for Arcellx's product, likely for competitive benchmarking purposes.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
43
Immix Biopharma | Investor Presentation Deck | 62 slidesImmix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
44
The table compares clinical trial inclusion criteria across four different therapies, focusing on prior lines of therapy, toxicity recovery, ECOG status, and measurable disease definitions.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
45
The slide highlights that NXC-201 has no exclusion for prior BCMA therapy, unlike the other listed treatments.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
51
The slide uses a bubble chart to map clinical trial outcomes and a table to detail specific drug performance metrics across treatment lines.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
52
The chart on the left is a conceptual visualization rather than a standard data plot, emphasizing the 100% heavily pre-treated patient population.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
70
Includes non-GAAP financial measure disclaimer.Innovid | Investor Day Presentation Deck | 74 slides · Innovid
Conference presentation Investor relations 1 hit
71
Innovid | Investor Day Presentation Deck | 74 slidesInnovid | Investor Day Presentation Deck | 74 slides · Innovid
Conference presentation Investor relations 1 hit
72
The slide uses a 'bridge' visual to indicate operating leverage between historical margins and future targets.Innovid | Investor Day Presentation Deck | 74 slides · Innovid
Conference presentation Investor relations 1 hit
15
The data highlights the evolution of board governance metrics over a 13-year period.Kering | ESG Presentation Deck | 80 slides · Moelis & Company
Conference presentation Investor relations Beat · Current Reality (Pain)1 hit
18
The slide uses icons to represent each committee and provides a legend for acronyms used in the member list.Kering | ESG Presentation Deck | 80 slides · Moelis & Company
Conference presentation Investor relations Beat · Current Reality (Pain)1 hit
26
The table compares remuneration structures across two roles and two voting years (2022 AGM vs 2023 AGM).Kering | ESG Presentation Deck | 80 slides · Moelis & Company
Conference presentation Investor relations Beat · Future Vision (Gain)1 hit
28
The chart illustrates a piecewise linear function for bonus payout based on performance targets.Kering | ESG Presentation Deck | 80 slides · Moelis & Company
Conference presentation Investor relations Beat · Future Vision (Gain)1 hit
31
The table outlines a complex incentive structure involving financial targets (80%), ESG targets (20%), and a relative share price performance modifier (+/- 50%).Kering | ESG Presentation Deck | 80 slides · Moelis & Company
Conference presentation Investor relations Beat · Future Vision (Gain)1 hit